Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.
Journal
International journal of Alzheimer's disease
ISSN: 2090-8024
Titre abrégé: Int J Alzheimers Dis
Pays: United States
ID NLM: 101525141
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
09
2021
accepted:
16
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Aducanumab, a new monoclonal antibody that targets In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized. Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.
Sections du résumé
Background
UNASSIGNED
Aducanumab, a new monoclonal antibody that targets
Objective
UNASSIGNED
In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized.
Methods
UNASSIGNED
Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched.
Results
UNASSIGNED
Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug.
Conclusion
UNASSIGNED
Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.
Identifiants
pubmed: 35308835
doi: 10.1155/2022/9343514
pmc: PMC8926483
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
9343514Informations de copyright
Copyright © 2022 Semira Abdi Beshir et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Curr Opin Psychiatry. 2020 May;33(3):284-291
pubmed: 32040044
JAMA Neurol. 2022 Jan 1;79(1):13-21
pubmed: 34807243
JAMA Neurol. 2020 Feb 1;77(2):215-224
pubmed: 31710340
Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7
pubmed: 26885819
Front Cell Neurosci. 2015 May 26;9:191
pubmed: 26074767
Alzheimers Dement. 2021 Apr;17(4):692-695
pubmed: 33656288
BMJ. 2021 Jul 5;374:n1682
pubmed: 34226181
Research (Wash D C). 2019 May 19;2019:5341375
pubmed: 31549066
J Intern Med. 2018 Dec;284(6):643-663
pubmed: 30051512
J Alzheimers Dis. 2019;68(4):1677-1686
pubmed: 30909223
J Pers Med. 2020 Dec 26;11(1):
pubmed: 33375220
Lancet Psychiatry. 2021 Nov;8(11):1013-1016
pubmed: 34087114
Alzheimers Dement. 2021 Sep;17(9):1487-1498
pubmed: 33938131
Sci Rep. 2018 Apr 23;8(1):6412
pubmed: 29686315
Eur J Neurol. 2021 Jan;28(1):e1
pubmed: 32808453
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Alzheimers Dis Rep. 2020 Feb 12;4(1):21-37
pubmed: 32206755
Chin Med J (Engl). 2018 Jul 05;131(13):1618-1624
pubmed: 29941717
BMJ. 2021 Feb 25;372:n156
pubmed: 33632704
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
N Engl J Med. 2021 May 6;384(18):1691-1704
pubmed: 33720637
Expert Opin Investig Drugs. 2019 Nov;28(11):967-975
pubmed: 31661331
Alzheimers Dement. 2020 Nov;16(11):1553-1560
pubmed: 31706733
Proteins. 2020 Dec;88(12):1592-1606
pubmed: 32666627
Alzheimers Res Ther. 2021 May 10;13(1):98
pubmed: 33971962
Biochem Pharmacol. 2020 Jul;177:113945
pubmed: 32247851
Nature. 2016 Aug 31;537(7618):50-6
pubmed: 27582220
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
Pharmacol Res. 2021 Sep;171:105754
pubmed: 34217830
Alzheimers Dement (N Y). 2016 Jun 20;2(3):169-176
pubmed: 29067304
Alzheimers Dement. 2020 Nov;16(11):1568-1570
pubmed: 32808733
J Biomed Sci. 2017 Jul 19;24(1):47
pubmed: 28720101
Nature. 2021 Jun;594(7863):309-310
pubmed: 34103732
Clin Med (Lond). 2016 Jun;16(3):247-53
pubmed: 27251914
J Alzheimers Dis. 2019;69(4):1031-1039
pubmed: 31156177
Dement Geriatr Cogn Disord. 2020;49(4):334-348
pubmed: 33321511
J Alzheimers Dis. 2016 Mar 29;52(2):417-20
pubmed: 27031492
Drug Discov Today. 2017 Apr;22(4):609-614
pubmed: 27989721
Alzheimers Dement. 2021 Jul;17(7):1145-1156
pubmed: 33491853
J Alzheimers Dis. 2020;77(4):1639-1653
pubmed: 32925044
Biotechnol Genet Eng Rev. 2019 Apr;35(1):26-45
pubmed: 30317930
Mol Neurodegener. 2020 Jul 16;15(1):40
pubmed: 32677986
JAMA. 2021 Oct 26;326(16):1627-1629
pubmed: 34499725
J Alzheimers Dis. 2018;64(s1):S611-S631
pubmed: 29865055
JAMA. 2021 May 4;325(17):1717-1718
pubmed: 33783469
Lancet Neurol. 2020 Feb;19(2):111-112
pubmed: 31978357
Dtsch Med Wochenschr. 2020 Feb;145(3):146-150
pubmed: 32018286
Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391
pubmed: 27678025
J Alzheimers Dis. 2015;45(1):75-88
pubmed: 25537011
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588
pubmed: 28653357
Front Neurosci. 2018 Jan 30;12:25
pubmed: 29440986
Alzheimers Dement. 2021 Apr;17(4):696-701
pubmed: 33135381
Dement Geriatr Cogn Disord. 2013;35(5-6):325-36
pubmed: 23594991
BMJ. 2021 Jun 11;373:n1503
pubmed: 34117086